Biotech M&A hits $106B in 2026, on track for strongest year since 2019 amid patent cliffs and China interest.
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
